Aura Biosciences, Inc. (AURA) Financial Statements
Free cash flow over the same period: -$103.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AURAAura Biosciences, Inc.Follow AURA — free
—
Price chart with a free account
- Market cap
- 653.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 25.2 | 42.2 | 65.2 | 73.3 | 90.3 | 102.8 | |
| Operating income | -35.3 | -60.3 | -85.0 | -96.1 | -112.8 | -138.1 | |
| Pre-tax income | -35.3 | -58.8 | -76.3 | -86.8 | -106.1 | -130.9 | |
| Income tax | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Net income | -35.3 | -58.8 | -76.4 | -86.9 | -106.2 | -131.0 | |
| Diluted EPS ($) | -8.95 | -1.96 | -1.93 | -1.75 | -1.76 | -1.38 | |
| Diluted shares (mn) | — | 29.9 | 39.6 | 49.7 | 60.3 | — |
USD millions · SEC XBRL
Aura Biosciences, Inc. — questions
- What is Aura Biosciences, Inc.'s net income?
- -$131.0M over the twelve months to 2026-06-30.
- What is Aura Biosciences, Inc.'s free cash flow?
- -$103.4M over the twelve months to 2026-06-30.
- What are Aura Biosciences, Inc.'s diluted earnings per share?
- $-1.38 over the twelve months to 2026-06-30.
Every figure on this page comes from Aura Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.